Want to see AIMD full AI Analyst Report?
Top Page
Ainos
(NASDAQ:AIMD)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.92
▼(-35.07% Downside)
Action:Reiterated
Date:10/17/26
The score is primarily held down by very weak financial performance (minimal/declining revenue, large ongoing losses, persistent cash burn, and sharply reduced equity increasing leverage risk) and bearish technicals (strong downtrend with negative MACD and very weak RSI/Stoch). Positive corporate developments (licensing agreement and governance upgrades) provide some offset, but valuation support is limited due to unprofitability and no dividend.
Positive Factors
Licensing Upside
The VELDONA licensing agreement creates several potential revenue streams while retaining economic participation in future sublicensing. Although payments depend on technology transfer and development outcomes, the structure can add non-dilutive funding and expand the value captured from Ainos’s platform.
Negative Factors
Weak Revenue Scale
Very low and declining revenue indicates that Ainos has not yet established meaningful commercial scale. Large ongoing losses and deeply negative margins show that the current cost base materially exceeds revenue, creating a persistent obstacle to breakeven and sustainable operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Licensing Upside
The VELDONA licensing agreement creates several potential revenue streams while retaining economic participation in future sublicensing. Although payments depend on technology transfer and development outcomes, the structure can add non-dilutive funding and expand the value captured from Ainos’s platform.
Read all positive factors
Ainos (AIMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.18M
Dividend YieldN/A
Average Volume (3M)249.36K
Price to Earnings (P/E)―
Beta (1Y)2.19
Revenue Growth-87.73%
EPS Growth51.12%
CountryUS
Employees41
SectorTechnology
Sector Strength88
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.52
Shares Outstanding7,384,073
10 Day Avg. Volume36,299
30 Day Avg. Volume249,361
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)56.41
P/FCF Ratio-1.51
Enterprise Value/Market Cap4.31
Enterprise Value/Revenue1.96K
Enterprise Value/Gross Profit-5.60
Enterprise Value/Ebitda-2.98
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ainos Business Overview & Revenue Model
Company Description
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, ...
Ainos Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
22
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.60K | 124.16K | 20.73K | 122.11K | 3.52M | 594.56K |
| Gross Profit | -4.76M | -4.68M | -31.87K | -253.73K | 1.41M | 410.38K |
| EBITDA | -8.96M | -9.28M | -9.44M | -8.75M | -9.12M | -1.83M |
| Net Income | -14.45M | -14.77M | -14.86M | -13.77M | -14.01M | -3.89M |
Balance Sheet | ||||||
| Total Assets | 19.56M | 20.87M | 28.82M | 31.84M | 37.11M | 40.82M |
| Cash, Cash Equivalents and Short-Term Investments | 1.42M | 417.35K | 3.89M | 1.89M | 1.85M | 1.75M |
| Total Debt | 13.81M | 11.00M | 12.00M | 5.96M | 1.27M | 3.62M |
| Total Liabilities | 16.28M | 13.31M | 13.30M | 7.39M | 2.48M | 30.63M |
| Stockholders Equity | 3.28M | 7.56M | 15.52M | 24.45M | 34.63M | 10.20M |
Cash Flow | ||||||
| Free Cash Flow | -4.49M | -4.65M | -5.83M | -4.79M | -3.67M | -1.39M |
| Operating Cash Flow | -4.47M | -4.61M | -5.81M | -4.69M | -3.04M | -1.25M |
| Investing Cash Flow | 23.12K | -2.22K | -125.29K | -101.53K | -630.18K | -180.52K |
| Financing Cash Flow | 4.70M | 1.01M | 8.03M | 4.92M | 3.85M | 3.15M |
Ainos Technical Analysis
Negative
1.42
Price Trends
1.31
Negative
1.52
Negative
1.62
Negative
Market Momentum
-0.14
Positive
19.33
Positive
14.53
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIMD, the sentiment is Negative. The current price of 1.42 is above the 20-day moving average (MA) of 1.11, above the 50-day MA of 1.31, and below the 200-day MA of 1.62, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 19.33 is Positive, neither overbought nor oversold. The STOCH value of 14.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIMD.
Ainos Risk Analysis
Ainos disclosed 52 risk factors in its most recent earnings report. Ainos reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Expansion into industrial and other non-healthcare environments may expose AI Nose to new and unforeseen risks. Q4, 2025
2.
We rely on the availability of licenses to third-party technology that may be difficult to replace or that may cause errors or delay implementation of our software and services should we not be able to continue or obtain a commercially reasonable license to such technology. Q4, 2025
3.
Our reliance on third-party components and cloud infrastructure could disrupt AI Nose operations, and any errors, disruption, performance problems, or failure in their or our operational infrastructure could adversely affect our business, financial condition, and results of operations. Q4, 2025
Ainos Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
45 Neutral | $10.58M | -1.14 | -47.22% | ― | -91.94% | 55.29% | |
42 Neutral | $6.18M | -0.33 | -217.50% | ― | -87.73% | 51.12% | |
42 Neutral | $7.94M | -0.29 | -181.02% | ― | ― | 66.94% | |
42 Neutral | $7.46M | -1.01 | -70.81% | ― | ― | 56.99% | |
41 Neutral | $6.33M | -0.16 | -536.78% | ― | ― | 22.10% |
* Technology Sector Average
AIMD
Ainos
0.84
-2.76
-76.75%
BLRX
Bioline RX Ltd Sponsored ADR
2.04
-1.72
-45.74%
SNGX
Soligenix
0.37
-1.20
-76.60%
CMMB
Chemomab Therapeutics
1.03
-2.02
-66.23%
FBLG
FibroBiologics, Inc.
0.95
-7.71
-89.02%
Ainos Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Ainos Updates Corporate Governance, Formalizes Classified Board
Positive
Oct 16, 2026
On October 14, 2026, Ainos, Inc. adopted amended Corporate Governance Policies that formalize a classified board structure divided into three staggered classes serving three-year terms. The policies clarify how directors are selected, how vacancie...
Business Operations and Strategy
Ainos Licenses VELDONA Platform, Shifts Focus to Chemical Intelligence
Positive
Sep 28, 2026
On September 24, 2026, Ainos granted Taiwan-based BioPhoenix a global, exclusive and sublicensable license to develop and commercialize its VELDONA oral interferon alpha technology for Sjögren’s disease and thrombocytopenia, with Ainos ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.